Vivos Therapeutics, Inc. (VVOS) stock
VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.10+0.00 (+2.40%)
Close on Nov 13, 2026Market cap $1.97MP/E –Yield –
Vivos Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Vivos Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -107.9%. For fiscal 2025 it was -114.1%, against -74.3% the year before. The highest annual figure on record is -74.3% in fiscal 2024.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -114.1% | −39.7 |
| FY2024 | Dec 31, 2024 | -74.3% | +51.0 |
| FY2023 | Dec 31, 2023 | -125.3% | +30.9 |
| FY2022 | Dec 31, 2022 | -156.2% | −35.5 |
| FY2021 | Dec 31, 2021 | -120.7% | −28.6 |
| FY2020 | Dec 31, 2020 | -92.1% | +0.7 |
| FY2019 | Dec 31, 2019 | -92.8% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -93.6% | +33.7 |
| Q1 FY2026 | Mar 31, 2026 | -128.7% | +1.2 |
| Q4 FY2025 | Dec 31, 2025 | -166.9% | −91.0 |
| Q3 FY2025 | Sep 30, 2025 | -69.8% | −1.3 |
| Q2 FY2025 | Jun 30, 2025 | -127.4% | −79.6 |
| Q1 FY2025 | Mar 31, 2025 | -129.9% | −19.2 |
| Q4 FY2024 | Dec 31, 2024 | -75.9% | +51.4 |
| Q3 FY2024 | Sep 30, 2024 | -68.5% | +41.7 |
| Q2 FY2024 | Jun 30, 2024 | -47.8% | +85.3 |
| Q1 FY2024 | Mar 31, 2024 | -110.7% | +19.1 |
| Q4 FY2023 | Dec 31, 2023 | -127.2% | +26.2 |
| Q3 FY2023 | Sep 30, 2023 | -110.3% | +17.1 |
| Q2 FY2023 | Jun 30, 2023 | -133.0% | +33.4 |
| Q1 FY2023 | Mar 31, 2023 | -129.8% | +52.4 |
| Q4 FY2022 | Dec 31, 2022 | -153.5% | +15.2 |
| Q3 FY2022 | Sep 30, 2022 | -127.3% | −6.3 |
| Q2 FY2022 | Jun 30, 2022 | -166.4% | −76.1 |
| Q1 FY2022 | Mar 31, 2022 | -182.2% | −83.4 |
| Q4 FY2021 | Dec 31, 2021 | -168.7% | +20.3 |
| Q3 FY2021 | Sep 30, 2021 | -121.1% | −65.8 |
| Q2 FY2021 | Jun 30, 2021 | -90.3% | −47.0 |
| Q1 FY2021 | Mar 31, 2021 | -98.8% | −18.8 |
| Q4 FY2020 | Dec 31, 2020 | -188.9% | – |
| Q3 FY2020 | Sep 30, 2020 | -55.2% | – |
| Q2 FY2020 | Jun 30, 2020 | -43.3% | – |
| Q1 FY2020 | Mar 31, 2020 | -80.0% | – |
See a number that looks wrong?